Investigational Drug Laquinimod Helped Treat Lupus Nephritis in Phase 2 Trial

Results of a Phase 2 trial showed that the investigational drug laquinimod improved kidney function in patients with lupus nephritis. The data was reported today at the European League Against Rheumatism (EULAR)  Annual European Congress of Rheumatology in Madrid. Based on these positive results, a  larger  clinical  trial  of  laquinimod  in combination with standard of care (mycophenolate mofetil and corticosteroids), compared to standard of care alone, is  planned among patients with lupus nephritis  to further evaluate the safety and efficacy of the drug.